Payment overview · 2025
General Payments
$377.28
20 reported records · 9 companies
Healthcare provider profile · identity verified
John J Solomon, DO
Allopathic & Osteopathic Physicians|Family Medicine · NORTH SMITHFIELD, RI · NPI 1861529158
Verified facts
What the public records show
CMS Open Payments records show John J Solomon, DO received $377.28 in general payments during 2025 across 20 reported records.
PFIZER INC. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.84 | 38.1% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.19 | 13.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.34 | 11.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.09 | 9.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.95 | 8.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.00 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.92 | 5.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.20 | 4.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.75 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.28 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $129.26 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $129.26 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.19 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.34 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.09 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.09 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 19 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 113 |
| Lisinopril | Lisinopril | 297 | 82 |
| Prednisone | Prednisone | 232 | 208 |
| Azithromycin | Azithromycin | 213 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 198 | 56 |
| Enalapril Maleate | Enalapril Maleate | 195 | 53 |
| Clonazepam | Clonazepam | 181 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 60 |
| Omeprazole | Omeprazole | 159 | 45 |
| Metformin Hcl | Metformin Hcl | 157 | 42 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 152 | 140 |
| Methylprednisolone | Methylprednisolone | 138 | 123 |
| Glimepiride | Glimepiride | 129 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 96 |
| Sertraline Hcl | Sertraline Hcl | 121 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 116 | 28 |
| Alprazolam | Alprazolam | 115 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 73 |
| Meloxicam | Meloxicam | 103 | 32 |
| Eliquis | Apixaban | 100 | 25 |
| Simvastatin | Simvastatin | 98 | 26 |
| Famotidine | Famotidine | 93 | 31 |
| Gabapentin | Gabapentin | 93 | 29 |
| Cephalexin | Cephalexin | 91 | 87 |
| Amoxicillin | Amoxicillin | 86 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 73 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 71 |
| Alendronate Sodium | Alendronate Sodium | 71 | 18 |
| Metformin Hcl Er | Metformin Hcl | 71 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 66 |
| Allopurinol | Allopurinol | 67 | 16 |
| Valsartan | Valsartan | 65 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 39 |
| Losartan Potassium | Losartan Potassium | 62 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Furosemide | Furosemide | 59 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 16 |
| Ibuprofen | Ibuprofen | 54 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 43 |
| Atenolol | Atenolol | 48 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Finasteride | Finasteride | 41 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 40 |
| Nifedipine Er | Nifedipine | 39 | 12 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Erythromycin | Erythromycin Base | 24 | 24 |
| Methocarbamol | Methocarbamol | 24 | 22 |
| Diazepam | Diazepam | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 21 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Naproxen | Naproxen | 18 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Victoza 3-Pak | Liraglutide | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 12 |
| Mometasone Furoate | Mometasone Furoate | 15 | 13 |
| Azelastine Hcl | Azelastine Hcl | 14 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.28 · 20 records | PFIZER INC. | AIRSUPRA, AREXVY, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, M-M-R II, MOUNJARO, NURTEC ODT, PAXLOVID, PROQUAD, SHINGRIX, VRAYLAR, ZEPBOUND, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error